Molecular targeted agents--where we are and where we are going.

Chin J Cancer · 2013 · PMC3845551 · PMID 23642906

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

Interim analysis of overall survival (OS) showed a strong trend in favor of the pertuzumab plus trastuzumab plus docetaxel regimen [2] .

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.